Drug intelligence / Profile preview

KD103

Development stage: Preclinical
Lead developer: Kwang Dong Pharmaceutical
Modality: Small Molecules

Overview

KD103 is an experimental drug candidate being developed by Kwang Dong Pharmaceutical in collaboration with Seoul National University for the treatment of Alzheimer's disease. Currently in the preclinical stage, KD103 is a multi-target therapeutic agent designed to address the complex pathology of the disease. It is reported to function by inhibiting the aggregation of amyloid-beta and tau proteins, which are hallmark features of Alzheimer's neurodegeneration. The technology for KD103 was licensed from Seoul National University to expand Kwang Dong's central nervous system (CNS) research and development pipeline.

Targets

Aβ (Amyloid-beta peptides and aggregates)MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on KD103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KD103.

Explore the full profile